{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:43:28Z","timestamp":1794210208953,"version":"4.8.0"},"reference-count":46,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Some patients with locally advanced\/metastatic non-small cell lung cancer (NSCLC) respond poorly to anti-programmed cell death protein 1 (PD-1)\/anti-programmed death-ligand 1 (PD-L1) treatments. Combination with other agents may improve the outcomes. This open-label, multicenter, phase 1b trial investigated the combination of sitravatinib, a spectrum-selective tyrosine kinase inhibitor, plus anti-PD-1 antibody tislelizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with locally advanced\/metastatic NSCLC were enrolled (Cohorts A, B, F, H, and I; N=22\u201324 per cohort). Cohorts A and F included patients previously treated with systemic therapy, with anti-PD-(L)1-resistant\/refractory non-squamous (cohort A) or squamous (cohort F) disease. Cohort B included patients previously treated with systemic therapy, with anti-PD-(L)1-na\u00efve non-squamous disease. Cohorts H and I included patients without prior systemic therapy for metastatic disease, no prior anti-PD-(L)1\/immunotherapy, with PD-L1-positive non-squamous (cohort H) or squamous (cohort I) histology. Patients received sitravatinib 120\u2009mg orally one time per day plus tislelizumab 200\u2009mg intravenously every 3 weeks, until study withdrawal, disease progression, unacceptable toxicity, or death. The primary endpoint was safety\/tolerability among all treated patients (N=122). Secondary endpoints included investigator-assessed tumor responses and progression-free survival (PFS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median follow-up was 10.9 months (range: 0.4\u201330.6). Treatment-related adverse events (TRAEs) occurred in 98.4% of the patients, with \u2265Grade 3 TRAEs in 51.6%. TRAEs led to discontinuation of either drug in 23.0% of the patients. Overall response rate was 8.7% (n\/N: 2\/23; 95%\u2009CI: 1.1% to 28.0%), 18.2% (4\/22; 95% CI: 5.2% to 40.3%), 23.8% (5\/21; 95% CI: 8.2% to 47.2%), 57.1% (12\/21; 95% CI: 34.0% to 78.2%), and 30.4% (7\/23; 95% CI: 13.2% to 52.9%) in cohorts A, F, B, H, and I, respectively. Median duration of response was not reached in cohort A and ranged from 6.9 to 17.9 months across other cohorts. Disease control was achieved in 78.3\u201390.9% of the patients. Median PFS ranged from 4.2 (cohort A) to 11.1 months (cohort H).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with locally advanced\/metastatic NSCLC, sitravatinib plus tislelizumab was tolerable for most patients, with no new safety signals and overall safety profiles consistent with known profiles of these agents. Objective responses were observed in all cohorts, including in patients na\u00efve to systemic and anti-PD-(L)1 treatments, or with anti-PD-(L)1 resistant\/refractory disease. Results support further investigation in selected NSCLC populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03666143\">NCT03666143<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-006055","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T09:40:16Z","timestamp":1676886016000},"page":"e006055","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03666143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04921358","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04471428","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03976375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05106335","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04921358","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03976375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05106335","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jun","family":"Zhao","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-9459","authenticated-orcid":false,"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Tianjin Cancer Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[{"name":"Blacktown Hospital and University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"Meili","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Day","sequence":"additional","affiliation":[{"name":"Medical Oncology, Monash Health and Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[{"name":"Medical Oncology, Nucleus Network, Melbourne, VIC, Australia and Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine - Oncology, Shandong Cancer Hospital & Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"BeiGene (Beijing) Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Peng","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"2025100315273339000_11.2.e006055.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100315273339000_11.2.e006055.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2025100315273339000_11.2.e006055.3","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab012","article-title":"Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: meta-analysis of metastatic NSCLC trials","volume":"5","author":"Man","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"2025100315273339000_11.2.e006055.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"2025100315273339000_11.2.e006055.5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100315273339000_11.2.e006055.6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100315273339000_11.2.e006055.7","doi-asserted-by":"crossref","first-page":"1758835920937902","DOI":"10.1177\/1758835920937902","article-title":"Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2025100315273339000_11.2.e006055.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01260-z"},{"key":"2025100315273339000_11.2.e006055.9","doi-asserted-by":"crossref","first-page":"107694","DOI":"10.1016\/j.pharmthera.2020.107694","article-title":"Combination therapy with PD-1\/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms","volume":"219","author":"Huang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2025100315273339000_11.2.e006055.10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"2025100315273339000_11.2.e006055.11","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12522"},{"key":"2025100315273339000_11.2.e006055.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112291","article-title":"Synergies of targeting tumor angiogenesis and immune checkpoints in non-small cell lung cancer and renal cell cancer: from basic concepts to clinical reality","volume":"18","author":"Pircher","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025100315273339000_11.2.e006055.13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0676"},{"key":"2025100315273339000_11.2.e006055.14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC\u2019 loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"key":"2025100315273339000_11.2.e006055.15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to fc\u03b3R\u03b9 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100315273339000_11.2.e006055.16","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT039","article-title":"Abstract CT039: results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (tax) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res"},{"key":"2025100315273339000_11.2.e006055.17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100315273339000_11.2.e006055.18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100315273339000_11.2.e006055.19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025100315273339000_11.2.e006055.20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100315273339000_11.2.e006055.21","doi-asserted-by":"crossref","first-page":"554313","DOI":"10.3389\/fonc.2020.554313","article-title":"Adverse effects of anti-PD-1\/PD-L1 therapy in non-small cell lung cancer","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol"},{"key":"2025100315273339000_11.2.e006055.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcsup.2013.07.016"},{"key":"2025100315273339000_11.2.e006055.23","first-page":"S505","article-title":"P1.01-108 management of anlotinib-related adverse events: data from ALTER 0303","volume":"13","author":"Si","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100315273339000_11.2.e006055.24","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2021.10.172","article-title":"153P safety\/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)","volume":"32","author":"Goh","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100315273339000_11.2.e006055.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.10.175","article-title":"156P safety\/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD- (L) 1-refractory\/resistant unresectable or metastatic melanoma from a phase ib study","volume":"32","author":"Cui","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100315273339000_11.2.e006055.26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2022.40.4_suppl.418","article-title":"Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (PTS) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100315273339000_11.2.e006055.27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10637-022-01274-y","article-title":"First-In-Human phase 1\/1b study to evaluate sitravatinib in patients with advanced solid tumors","volume":"40","author":"Bauer","year":"2022","journal-title":"Invest New Drugs"},{"key":"2025100315273339000_11.2.e006055.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1796","article-title":"1191O MRTX-500: phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (PTS) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy","volume":"32","author":"Leal","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100315273339000_11.2.e006055.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2025100315273339000_11.2.e006055.30","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"FP13.04 KEYNOTE-042 3-year survival update: 1L pembrolizumab vs platinum-based chemotherapy for PD-L1+ locally advanced\/metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100315273339000_11.2.e006055.31","doi-asserted-by":"crossref","first-page":"103538","DOI":"10.1016\/j.critrevonc.2021.103538","article-title":"Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?","volume":"169","author":"Insa","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100315273339000_11.2.e006055.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70385-0"},{"key":"2025100315273339000_11.2.e006055.33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28132"},{"key":"2025100315273339000_11.2.e006055.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2025100315273339000_11.2.e006055.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"2025100315273339000_11.2.e006055.36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","article-title":"Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases","volume":"81","author":"Fujita","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025100315273339000_11.2.e006055.37","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13543"},{"key":"2025100315273339000_11.2.e006055.38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/1759-7714.13241","article-title":"Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody","volume":"11","author":"Fujita","year":"2020","journal-title":"Thorac Cancer"},{"key":"2025100315273339000_11.2.e006055.39","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review","volume":"11","author":"Kitagawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"2025100315273339000_11.2.e006055.40","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010102","article-title":"Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer","volume":"9","author":"Katayama","year":"2019","journal-title":"J Clin Med"},{"key":"2025100315273339000_11.2.e006055.41","doi-asserted-by":"crossref","first-page":"32298","DOI":"10.18632\/oncotarget.25949","article-title":"Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer","volume":"9","author":"Niki","year":"2018","journal-title":"Oncotarget"},{"key":"2025100315273339000_11.2.e006055.42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jitc-2021-003476","article-title":"Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study","volume":"9","author":"Oliva","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100315273339000_11.2.e006055.43","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2022.40.16_suppl.9005","article-title":"Cabozantinib (C) plus atezolizumab (a) or C alone in patients (PTS) with advanced non\u2013small cell lung cancer (ansclc) previously treated with an immune checkpoint inhibitor (ICI): results from cohorts 7 and 20 of the COSMIC-021 study","volume":"40","author":"Neal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100315273339000_11.2.e006055.44","unstructured":"ClinicalTrials.gov . Tislelizumab in combination with sitravatinib in patients with locally advanced or metastatic non-small cell lung cancer. 2022. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04921358"},{"key":"2025100315273339000_11.2.e006055.45","unstructured":"ClinicalTrials.gov . Efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080\/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (MK-7902-008\/E7080-G000-316\/LEAP-008). 2022. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03976375"},{"key":"2025100315273339000_11.2.e006055.46","unstructured":"Clinicaltrials.gov . A study to evaluate camrelizumab combined with famitinib as subsequent therapy in patients with advanced NSCLC. 2022. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05106335"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:27:42Z","timestamp":1759530462000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/jitc-2022-006055"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006055","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}